CNR Institutional Research Information System

CHIARINI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.159
NA - Nord America 915
EU - Europa 197
SA - Sud America 191
Continente sconosciuto - Info sul continente non disponibili 19
AF - Africa 15
OC - Oceania 3
Totale 2.499
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 867
SG - Singapore 463
CN - Cina 312
BR - Brasile 158
HK - Hong Kong 101
VN - Vietnam 100
KR - Corea 59
IT - Italia 53
FR - Francia 51
BD - Bangladesh 29
CA - Canada 23
IN - India 19
DE - Germania 15
AR - Argentina 14
FI - Finlandia 14
IL - Israele 13
JP - Giappone 13
NL - Olanda 12
CO - Colombia 9
GB - Regno Unito 8
ID - Indonesia 8
TR - Turchia 7
ES - Italia 5
JM - Giamaica 5
MX - Messico 5
PL - Polonia 5
EC - Ecuador 4
RS - Serbia 4
SA - Arabia Saudita 4
SE - Svezia 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
CR - Costa Rica 3
EG - Egitto 3
IQ - Iraq 3
MY - Malesia 3
AL - Albania 2
AZ - Azerbaigian 2
BG - Bulgaria 2
CL - Cile 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
HN - Honduras 2
IE - Irlanda 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
PH - Filippine 2
PY - Paraguay 2
RU - Federazione Russa 2
SN - Senegal 2
SV - El Salvador 2
TH - Thailandia 2
UA - Ucraina 2
AT - Austria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
CD - Congo 1
CH - Svizzera 1
DZ - Algeria 1
EE - Estonia 1
GD - Grenada 1
GR - Grecia 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
JO - Giordania 1
KY - Cayman, isole 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 2.480
Salva come PNG Salva come JPEG
Città #
Santa Clara 324
Singapore 269
Hefei 151
Hong Kong 98
San Jose 92
Beijing 60
Seoul 59
Ashburn 54
Ho Chi Minh City 44
Lauterbourg 41
Los Angeles 41
Hanoi 26
Dallas 18
New York 17
São Paulo 15
Buffalo 11
Helsinki 11
Orem 9
Chicago 8
Minamishinagawa 8
Houston 7
Phoenix 7
Bengaluru 6
Newark 6
Rio de Janeiro 6
Brooklyn 5
Kingston 5
Montreal 5
Council Bluffs 4
Da Nang 4
Istanbul 4
Toronto 4
Alexandria 3
Atlanta 3
Baltimore 3
Belgrade 3
Biên Hòa 3
Bologna 3
Brasília 3
Curitiba 3
Falkenstein 3
Frankfurt am Main 3
Maceió 3
Medellín 3
Quincy 3
Rialto 3
San Francisco 3
Seattle 3
Tel Aviv 3
The Bronx 3
Thái Bình 3
Tokyo 3
Venice 3
Volta Redonda 3
Warsaw 3
Ampang 2
Ankara 2
Baghdad 2
Bandung 2
Bassett 2
Bauru 2
Belo Horizonte 2
Bishkek 2
Boardman 2
Bogotá 2
Boston 2
Bắc Giang 2
Calgary 2
Charlotte 2
Chennai 2
Chino 2
Dakar 2
Denver 2
Des Moines 2
Dhaka 2
Dublin 2
Feira de Santana 2
Fortaleza 2
Fresno 2
Genoa 2
Guatemala City 2
Hortolândia 2
Hải Dương 2
Johannesburg 2
Lancaster 2
Lappeenranta 2
Lombard 2
Macaé 2
Manchester 2
Milan 2
Modena 2
Mossoró 2
Mumbai 2
Munich 2
Nha Trang 2
Norristown 2
Nova Iguaçu 2
Nuremberg 2
Orlando 2
Padova 2
Totale 1.578
Salva come PNG Salva come JPEG
Nome #
Lamin A and Prelamin a Counteract Migration of Osteosarcoma Cells 104
The role played by wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia 100
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-?B. 85
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 84
Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model. 77
Advances in targeting signal transduction pathways. 76
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. 74
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 64
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. 63
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. 61
Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 60
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 60
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 56
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 55
LTER Macrosito IT17-M Stazioni Di Ricerca In Antartide- Mooring B: North Central Ross Sea, Joides Basin - Antarctica 54
The unfolded protein response: A novel therapeutic target in acute leukemias 52
Therapeutic targeting of CK2 in acute and chronic leukemias 49
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 49
Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm 48
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 48
LTER Macrosito IT17-M Stazioni Di Ricerca In Antartide- Mooring A: Southwestern Ross Sea, Ross Island 48
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. 47
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 47
GSK-3: a multifaceted player in acute leukemias 46
Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update 45
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 44
Activity of the selective I?B kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. 44
Phospholipase C-beta1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. 44
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. 43
Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells 42
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 41
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 41
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. 40
Inhibition of methyltransferase dot1l sensitizes to sorafenib treatment aml cells irrespective of mll-rearrangements: A novel therapeutic strategy for pediatric aml 39
Assessment of the structural and functional characteristics of human mesenchymal stem cells associated with a prolonged exposure of morphine 38
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. 37
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 36
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 35
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 34
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: Targeting the unfolded protein response signaling 34
MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia 34
Autophagy in acute leukemias: A double-edged sword with important therapeutic implications 33
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 32
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 31
PLCbeta1a and PLCbeta1b selective regulation and cyclin D3 modulation reduced by Kinamycin F during K562 cell differentiation. 30
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 29
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mtor cascades which alter therapy response 29
Current treatment strategies for inhibiting mTOR in cancer 28
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; Indications for novel therapeutics 28
K562 cell proliferation is modulated by PLC beta 1 through a PKC alpha-mediated pathway 28
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells 27
Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients 26
Totale 2.499
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.672
article - articoli 8.337
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 335
Totale 17.344
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20242 0 0 0 0 0 0 0 0 1 0 0 1
2024/2025944 7 2 64 33 273 67 11 61 33 13 201 179
2025/20261.309 96 142 96 260 210 55 177 58 54 72 56 33
2026/2027244 56 67 121 0 0 0 0 0 0 0 0 0
Totale 2.499